Eton Pharmaceuticals has announced the relaunch of HEMANGEOL (propranolol) Oral Solution, a critical therapy for infantile hemangioma, a rare pediatric vascular condition that can require urgent systemic treatment.

 

The company says the product will now be distributed exclusively through Anovo Specialty Pharmacy, a move designed to streamline access and speed up treatment initiation for infants in need. Alongside the relaunch, Eton has fully integrated its patient support program, Eton Cares, offering expanded assistance including a $0 co-pay option for eligible commercially insured patients and broader financial support programs.

 

“We are excited to deliver another major product launch for the company. HEMANGEOL is a critical and time-sensitive therapy where early treatment can meaningfully impact outcomes, and the only FDA-approved treatment for infantile hemangiomas. 

 

"With the integration of Eton Cares and a dedicated rare disease specialty pharmacy model, we are focused on helping patients start therapy quickly and ensuring families are supported from prescription through treatment. Our HEMANGEOL commercial team has been actively working with caregivers, healthcare professionals, and pharmacies to ensure a seamless transition for patients,” said Sean Brynjelsen, CEO of Eton Pharmaceuticals.

 

Medical experts emphasized the urgency of timely intervention in infantile hemangioma cases, which can grow rapidly in early infancy and, in some cases, lead to complications if untreated.

 

“Infantile hemangiomas can evolve rapidly, and timely intervention is critical. In practice, the challenge is often not recognizing when to treat but ensuring that infants can start therapy without delays. 

 

"Streamlined access to an FDA-approved treatment designed specifically for this population can meaningfully improve both outcomes and the care experience for families,” said Dr. Maria Gnarra Buethe, Division Chief of Dermatology, Rady Children’s Hospital of Orange County and Director of Pediatric Dermatology, University of California, Irvine.

 

Patient advocacy groups also underscored the narrow treatment window in early infancy.

 

“For families, an infantile hemangioma diagnosis is overwhelming and the window of opportunity to potentially prevent negative consequences is narrow. In order to prevent these adverse complications, prompt and early treatment is critical,” said Dr. Linda Rozell- Shannon, Founder & President of The Vascular Birthmarks Foundation, a global non-profit.